Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid Tumors
- 1 July 2021
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 27 (13), 3584-3594
- https://doi.org/10.1158/1078-0432.CCR-21-0238
Abstract
Purpose Inhibition of histone deacetylase 6 (HDAC6) is predicted to deliver both direct antitumor activity and modulation of the antitumor immune response. This study describes the development of a novel HDAC6 inhibitor. Patients and Methods: KA2507 was characterized in HDAC biochemical and cellular target engagement assays and in predinical efficacy models of melanoma and colorectal cancer. In a phase I study, KA2507 was administered orally using a 3+3 dose-escalation design (NCT03008018). Results: KA2507 is a potent and selective inhibitor of HDAC6 (biochemical IC50 = 2.5 nmol/L). Predinical models demonstrated antitumor efficacy in syngeneic tumor-bearing mice, with translational studies highlighting modulation of the antitumor immune response. Twenty patients were treated in a phase I study. KA2507 was well tolerated; dose-limiting toxicity was not observed up to the maximum dose administered. Pharmacokinetic profiling supported twice-daily oral dosing. Pharmacodynamic analysis demonstrated selective HDAC6 target engagement in peripheral blood cells, free from off-target class I HDAC activity. Stable disease was the best clinical response (7 patients). Three of these patients (adenoid cystic carcinoma, n = 2; rectal adenocarcinoma, n = 1) had prolonged disease stabilization that lasted for 16.4, 12.6, and 9.0 months, respectively. Conclusions: KA2507 is a potent and selective inhibitor of HDAC6 showing antitumor efficacy and immune modulatory effects in preclinical models. In a phase I study, KA2507 showed selective target engagement, no significant toxicities, and prolonged disease stabilization in a subset of patients. Further clinical studies of KA2507 are warranted, as a single agent or, preferably, combined with other immuno-oncology drugs.Other Versions
Funding Information
- NCI NIH (P30 CA016672)
This publication has 28 references indexed in Scilit:
- Presence of primary cilia in cancer cells correlates with prognosis of pancreatic ductal adenocarcinomaHuman Pathology, 2013
- Primary Cilia Are Lost in Preinvasive and Invasive Prostate CancerPLOS ONE, 2013
- HDAC6 Inhibition Restores Ciliary Expression and Decreases Tumor GrowthCancer Research, 2013
- Reduced cilia frequencies in human renal cell carcinomas versus neighboring parenchymal tissueCilia, 2013
- Primary cilia and aberrant cell signaling in epithelial ovarian cancerCilia, 2012
- Blockade of Programmed Death Ligand 1 Enhances the Therapeutic Efficacy of Combination Immunotherapy against MelanomaPublished by The American Association of Immunologists ,2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal Of Cancer, 2009
- HEF1-Dependent Aurora A Activation Induces Disassembly of the Primary CiliumCell, 2007
- HDAC6 Regulates Hsp90 Acetylation and Chaperone-Dependent Activation of Glucocorticoid ReceptorMolecular Cell, 2005
- Growth and Immunogenicity of Murine B-16 Melanoma*Journal of Investigative Dermatology, 1974